Trotabresib

CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors[1][2].

Product Specifications

CAS Number

[1706738-98-8]

Product Name Alternative

CC-90010

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cc-90010.html

Concentration

10mM

Purity

99.74

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C)C=C(C2=CC(S(=O)(C)=O)=CC=C2OCC3CC3)C4=C1C=CC=C4

Molecular Formula

C21H21NO4S

Molecular Weight

383.46

References & Citations

[1]CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.|[2]V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study.|[3]Holliday H, et al. Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma[J]. bioRxiv, 2024: 2024.06. 06.597703.